{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05475210",
            "orgStudyIdInfo": {
                "id": "MTTI-EBT-001"
            },
            "secondaryIdInfos": [
                {
                    "id": "21-362",
                    "type": "OTHER",
                    "domain": "Memorial Sloan-Kettering Cancer Center IRB"
                }
            ],
            "organization": {
                "fullName": "Molecular Targeting Technologies, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors",
            "officialTitle": "Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "dota-eb-tate-in-adult-patients-with-advanced-well-differentiated-neuroendocrine-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2022-06-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-22",
            "studyFirstSubmitQcDate": "2022-07-22",
            "studyFirstPostDateStruct": {
                "date": "2022-07-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Molecular Targeting Technologies, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "ClinSmart",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs."
        },
        "conditionsModule": {
            "conditions": [
                "Neuroendocrine Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 9,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Peptide Receptor Radionucleotide Therapy (PRRT)",
                    "type": "EXPERIMENTAL",
                    "description": "The treatment regimen will consist of a single-dose intravenous administration of 177Lu-DOTA-EB-TATE per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 3 different dose levels, from 50 mCi to 150 mCi (1.85 -5.55 GBq). Each dose of 177Lu-DOTA-EB-TATE will be administered in association with intravenous renal protective amino acid solutions.",
                    "interventionNames": [
                        "Drug: 177Lu-DOTA-EB-TATE",
                        "Other: Amino Acid Solution"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "177Lu-DOTA-EB-TATE",
                    "description": "Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.",
                    "armGroupLabels": [
                        "Peptide Receptor Radionucleotide Therapy (PRRT)"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Amino Acid Solution",
                    "description": "The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.",
                    "armGroupLabels": [
                        "Peptide Receptor Radionucleotide Therapy (PRRT)"
                    ],
                    "otherNames": [
                        "Arginine-Lysine Solution"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "To evaluate the safety of 177Lu-DOTA-EB-TATE assessed from the number of patients with treatment-related adverse events.",
                    "timeFrame": "16-17 months"
                },
                {
                    "measure": "To identify the dose-limiting toxicities (DLTs) of escalating doses of 177Lu-DOTA-EB-TATE up to 150 mCi.",
                    "timeFrame": "16-17 months"
                },
                {
                    "measure": "To determine if the maximum tolerated dose is among the explored doses of 50, 100 and 150 mCi.",
                    "timeFrame": "16-17 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To evaluate the differential safety of 177Lu-DOTA-EB-TATE, expressed as the number of patients with treatment-related adverse events following 177Lu-DOTA-EB-TATE.",
                    "timeFrame": "16-17 months"
                },
                {
                    "measure": "To evaluate dosimetry levels in patients following 2 cycles of 177Lu-DOTA-EB-TATE.",
                    "timeFrame": "16-17 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nAbility to understand and willing to sign a written informed consent document\n\nAged 18 years or older\n\nHistologically proven or cytologically confirmed, inoperable, GEP-NETs\n\nNeuroendocrine tumors (NETs) of grade 1, 2 and 3 according to World Health Organization (WHO) 2017 classification\n\nMeasurable disease as defined by Response Criteria in Solid Tumors (RECIST) version 1.1\n\nOverexpression of somatostatin receptors of the target lesions in 68Ga-DOTA-TATE positron emission tomography (PET)/computed tomography (CT) with SUV of lesions greater than normal liver in at least 1 lesion\n\nA Cockcroft Gault calculated creatinine clearance \\> 60 mL/min\n\nKarnofsky performance status scale \u2265 70%\n\nWomen of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including follow-up (7 months after the last dose of study drug for women and 4 months for men).\n\nPrevious local therapy (e.g., chemoembolization or bland embolization) is allowed if completed \\>4 weeks prior to study entry.\n\nPrevious surgery no less than 6 weeks prior to study entry.\n\nEither no prior treatment with 177Lu-DOTA-TATE or at least 12 months progression-free survival (PFS) after prior treatment with 177Lu-DOTA-TATE\n\nExclusion Criteria:\n\nWomen who are pregnant or breastfeeding\n\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-EB-TATE as assessed from medical records\n\nPrevious treatment with more than 4 cycles of 177Lu-DOTA-TATE\n\nParticipant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 4 weeks or 4 half-lives whichever is longer, before the first administration of study drug.\n\nParticipant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 3 months after the last dose of study drug.\n\nLife expectancy \\< 6 months as assessed by the treating physician\n\n\\> 80% liver involvement by tumor\n\n\\> 25% bone marrow involvement by tumor\n\nPoorly differentiated neuroendocrine neoplasms, such as poorly differentiated neuroendocrine carcinoma, small- and large-cell neuroendocrine carcinoma; mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN); Grade 3 neuroendocrine carcinomas (NEC)\n\nPresence of somatostatin receptor negative lesions if they cannot be addressed with loco-regional therapies prior to the treatment start\n\nDeteriorated renal function, as indicated by a serum creatinine clearance \\> 1.7 mg/dL\n\nDeteriorated bone marrow function\n\nDeteriorated liver function\n\nToxicities from prior therapies that have not resolved to grade 1 or grade 0\n\nActive and clinically significant bacterial, fungal, or viral infection, including hepatitis B (HBV), hepatitis C (HBC), know human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness\n\nKnown brain metastases and/or carcinomatous meningitis, unless these metastases have been treated and stabilized\n\nUncontrolled diabetes mellitus as defined by a HbA1c \\>9%\n\nImpossibility to interrupt short-acting octreotide for 24 h before and 24 h after the administration of 177Lu-DOTA-EB-TATE; impossibility to have an interval of \u22654 weeks between octreotide and 177Lu-DOTA-EB-TATE\n\nThe use of somatostatin and its analogues within 4 months of a planned 177Lu-DOTA-EB-TATE treatment\n\nUncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n\nPrior external beam radiation therapy involving \\>25% of the bone marrow\n\nUnmanageable urinary incontinence rendering the administration of 177Lu-DOTA-EB-TATE unsafe\n\nOther known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Chris Pak",
                    "role": "CONTACT",
                    "phone": "610-738-7938",
                    "email": "cpak@mtarget.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lisa Bodei, MD, PhD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lisa Bodei, MD, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "asFound": "Neuroendocrine Tumors",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "asFound": "Neuroendocrine Tumors",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019999",
                    "term": "Pharmaceutical Solutions"
                },
                {
                    "id": "C000654487",
                    "term": "(177)Lu-DOTA-EB-TATE"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019275",
                    "term": "Radiopharmaceuticals"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "asFound": "Procedure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M289599",
                    "name": "(177)Lu-DOTA-EB-TATE",
                    "asFound": "Vosaroxin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21258",
                    "name": "Radiopharmaceuticals",
                    "relevance": "LOW"
                },
                {
                    "id": "T1",
                    "name": "Arginine",
                    "asFound": "Healthy controls",
                    "relevance": "HIGH"
                },
                {
                    "id": "T11",
                    "name": "Lysine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}